These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 335348)

  • 1. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.
    Peltola H; Käyhty H; Sivonen A; Mäkelä H
    Pediatrics; 1977 Nov; 60(5):730-7. PubMed ID: 335348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory.
    Käyhty H; Karanko V; Peltola H; Mäkelä PH
    Pediatrics; 1984 Nov; 74(5):857-65. PubMed ID: 6387614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.
    Eskola J; Käyhty H; Takala AK; Peltola H; Rönnberg PR; Kela E; Pekkanen E; McVerry PH; Mäkelä PH
    N Engl J Med; 1990 Nov; 323(20):1381-7. PubMed ID: 2233904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.
    Peltola H; Käyhty H; Virtanen M; Mäkelä PH
    N Engl J Med; 1984 Jun; 310(24):1561-6. PubMed ID: 6610125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
    N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.
    Santosham M; Wolff M; Reid R; Hohenboken M; Bateman M; Goepp J; Cortese M; Sack D; Hill J; Newcomer W
    N Engl J Med; 1991 Jun; 324(25):1767-72. PubMed ID: 1903846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine on the incidence of epiglottitis and meningitis.
    Peltola H; Virtanen M; Mäkelä PH
    Pathol Biol (Paris); 1983 Feb; 31(2):141-3. PubMed ID: 6341944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with Haemophilus influenzae type b conjugate vaccines.
    Mäkelä PH; Eskola J; Peltola H; Takala AK; Käyhty H
    Pediatrics; 1990 Apr; 85(4 Pt 2):651-3. PubMed ID: 2179855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children.
    Käyhty H; Peltola H; Eskola J
    Pediatr Infect Dis J; 1988 Aug; 7(8):574-7. PubMed ID: 3050853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.
    Walter EB; Moggio MV; Drucker RP; Wilfert CM
    Pediatr Infect Dis J; 1990 Sep; 9(9):632-5. PubMed ID: 2235187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine.
    Shapiro ED; Berg AT
    Pediatrics; 1990 Apr; 85(4 Pt 2):643-7. PubMed ID: 2179854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy.
    Eskola J; Peltola H; Takala AK; Käyhty H; Hakulinen M; Karanko V; Kela E; Rekola P; Rönnberg PR; Samuelson JS
    N Engl J Med; 1987 Sep; 317(12):717-22. PubMed ID: 3306379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB).
    Vella PP; Staub JM; Armstrong J; Dolan KT; Rusk CM; Szymanski S; Greer WE; Marburg S; Kniskern PJ; Schofield TL
    Pediatrics; 1990 Apr; 85(4 Pt 2):668-75. PubMed ID: 2107517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilus influenzae type B disease in children vaccinated with type B polysaccharide vaccine.
    Granoff DM; Shackelford PG; Suarez BK; Nahm MH; Cates KL; Murphy TV; Karasic R; Osterholm MT; Pandey JP; Daum RS
    N Engl J Med; 1986 Dec; 315(25):1584-90. PubMed ID: 3491315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation.
    Ahonkhai VI; Lukacs LJ; Jonas LC; Matthews H; Vella PP; Ellis RW; Staub JM; Dolan KT; Rusk CM; Calandra GB
    Pediatrics; 1990 Apr; 85(4 Pt 2):676-81. PubMed ID: 2107518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months.
    Madore DV; Johnson CL; Phipps DC; Myers MG; Eby R; Smith DH
    Pediatrics; 1990 Oct; 86(4):527-34. PubMed ID: 2216616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive immunization for infection with Haemophilus influenzae type b.
    Santosham M; Reid R; Letson GW; Wolff MC; Siber G
    Pediatrics; 1990 Apr; 85(4 Pt 2):662-6. PubMed ID: 2179857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.